Drugs / haNK™ for Infusion
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03027128 | Aug 2017 → May 2019 | cancer | ImmunityBio, Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | haNK for Infusion | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03027128 ↗ |
| Modality | Cell therapy | “NK cell line” NCT03027128 ↗ |
| Route | Intravenous | “Suspension for Intravenous Infusion” NCT03027128 ↗ |